Byung Cheul Ahn

Title: Byung Cheul Ahn: Innovator in Angiogenesis Inhibitors

Introduction

Byung Cheul Ahn is a notable inventor based in Kyonggi-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of angiogenesis inhibitors. His work focuses on the purification processes of proteins that play a crucial role in cancer treatment.

Latest Patents

Ahn holds a patent for the "Process of purifying angiogenesis inhibitors." This invention relates to the purification of angiogenesis inhibitor proteins expressed in recombinant kringle 1-3, also known as greenstatin. The process involves solubilizing, refolding, and purifying the proteins to achieve a pure and active form. The purified greenstatin specifically suppresses endothelial cell proliferation, angiogenesis, and the growth of various cancers, including lung cancer, skin cancer, and brain tumors. This innovative process is applicable for the mass production of angiogenesis inhibitor proteins, which are beneficial for treating conditions such as glaucoma and retinopathy.

Career Highlights

Byung Cheul Ahn is associated with Korea Greencross Corporation, where he continues to advance his research and development efforts. His work has positioned him as a key figure in the biotechnology sector, particularly in the area of cancer therapeutics.

Collaborations

Ahn collaborates with notable colleagues, including Weon Kyoo You and Seung Ho So. Their combined expertise enhances the research and development initiatives at Korea Greencross Corporation.

Conclusion

Byung Cheul Ahn's innovative work in the purification of angiogenesis inhibitors represents a significant advancement in cancer treatment. His contributions are paving the way for new therapeutic options that can improve patient outcomes.